JP2021523114A5 - - Google Patents

Info

Publication number
JP2021523114A5
JP2021523114A5 JP2020561635A JP2020561635A JP2021523114A5 JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5 JP 2020561635 A JP2020561635 A JP 2020561635A JP 2020561635 A JP2020561635 A JP 2020561635A JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5
Authority
JP
Japan
Prior art keywords
lymphoma
celduratinib
cocrystal
solvate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523114A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030690 external-priority patent/WO2019213589A1/en
Publication of JP2021523114A publication Critical patent/JP2021523114A/ja
Publication of JP2021523114A5 publication Critical patent/JP2021523114A5/ja
Priority to JP2024001279A priority Critical patent/JP2024024093A/ja
Pending legal-status Critical Current

Links

JP2020561635A 2018-05-04 2019-05-03 リンパ腫の治療方法 Pending JP2021523114A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001279A JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862667249P 2018-05-04 2018-05-04
US62/667,249 2018-05-04
US201862678934P 2018-05-31 2018-05-31
US62/678,934 2018-05-31
US201862736047P 2018-09-25 2018-09-25
US62/736,047 2018-09-25
PCT/US2019/030690 WO2019213589A1 (en) 2018-05-04 2019-05-03 Methods for treating lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001279A Division JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Publications (2)

Publication Number Publication Date
JP2021523114A JP2021523114A (ja) 2021-09-02
JP2021523114A5 true JP2021523114A5 (cg-RX-API-DMAC7.html) 2022-05-18

Family

ID=66554509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561635A Pending JP2021523114A (ja) 2018-05-04 2019-05-03 リンパ腫の治療方法
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Country Status (11)

Country Link
US (3) US11266645B2 (cg-RX-API-DMAC7.html)
EP (1) EP3787628A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021523114A (cg-RX-API-DMAC7.html)
KR (1) KR20210003789A (cg-RX-API-DMAC7.html)
CN (1) CN112074271B (cg-RX-API-DMAC7.html)
AU (1) AU2019262644A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022430A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098012A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011817A (cg-RX-API-DMAC7.html)
TW (1) TW202014190A (cg-RX-API-DMAC7.html)
WO (1) WO2019213589A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
EP4436581A4 (en) * 2021-11-22 2025-08-13 Secura Bio Inc METHODS OF TREATING PERIPHERAL T-CELL LYMPHOMA
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院(南京医科大学第一附属医院) cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN117427166B (zh) * 2023-09-25 2024-09-10 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
CA2594542C (en) 2005-01-10 2014-03-25 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2016196385A1 (en) * 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
EP3383396B1 (en) * 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma

Similar Documents

Publication Publication Date Title
EP4110338A1 (en) A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
Fenelon et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
RU2015120616A (ru) Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US20040029869A1 (en) Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
JP2018520117A5 (cg-RX-API-DMAC7.html)
EP3010505A1 (en) Pharmaceutical combinations
JP2024542984A5 (cg-RX-API-DMAC7.html)
JP2021522246A (ja) 癌治療のための併用
HUE028025T2 (en) Use of Panobinostat HDAC inhibitor to treat myeloma
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
JP2006508118A5 (cg-RX-API-DMAC7.html)
JP2025529240A5 (cg-RX-API-DMAC7.html)
JP2024517788A (ja) Mpnstの処置のための化合物及び組成物
Freerksen et al. Malaria therapy and prophylaxis with cotrifazid, a multiple complex combination consisting of rifampicin+ isoniazid+ sulfamethoxazole+ trimethoprim
RU2020137882A (ru) Способы лечения лимфомы
EP3130339B1 (en) A compound for use in the treatment of comorbid anxiety disorder and depression disorder
CN101282728A (zh) 有机化合物的组合
NZ788615B2 (en) Dosing of a bruton's tyrosine kinase inhibitor
Greenblatt et al. Rational Use of psychotropic drugs IV. Antidepressants
Dunn et al. Leflunomide: an immunomodulatory agent for the treatment of rheumatoid arthritis
US20240207274A1 (en) Larotrectinib and moderate CYP3A4 inducer
Claghorn et al. Recent developments in antidepressant agents
Gupta Phentermine and topiramate combination for chronic weight management: a review